{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:04:05Z","timestamp":1793293445495,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with rising incidence and with 5-years overall survival of less than 8%. PDAC creates an immune-suppressive tumor microenvironment to escape immune-mediated eradication. Regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSC) are critical components of the immune-suppressive tumor microenvironment. Shifting from tumor escape or tolerance to elimination is the major challenge in the treatment of PDAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In a mathematical model, we combine distinct treatment modalities for PDAC, including 5-FU chemotherapy and anti- CD25 immunotherapy to improve clinical outcome and therapeutic efficacy. To address and optimize 5-FU and anti- CD25 treatment (to suppress MDSCs and Tregs, respectively) schedule in-silico and simultaneously unravel the processes driving therapeutic responses, we designed an in vivo calibrated mathematical model of tumor-immune system (TIS) interactions. We designed a user-friendly graphical user interface (GUI) unit which is configurable for treatment timings to implement an in-silico clinical trial to test different timings of both 5-FU and anti- CD25 therapies. By optimizing combination regimens, we improved treatment efficacy. In-silico assessment of 5-FU and anti- CD25 combination therapy for PDAC significantly showed better treatment outcomes when compared to 5-FU and anti- CD25 therapies separately. Due to imprecise, missing, or incomplete experimental data, the kinetic parameters of the TIS model are uncertain that this can be captured by the fuzzy theorem. We have predicted the uncertainty band of cell\/cytokines dynamics based on the parametric uncertainty, and we have shown the effect of the treatments on the displacement of the uncertainty band of the cells\/cytokines. We performed global sensitivity analysis methods to identify the most influential kinetic parameters and simulate the effect of the perturbation on kinetic parameters on the dynamics of cells\/cytokines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings outline a rational approach to therapy optimization with meaningful consequences for how we effectively design treatment schedules (timing) to maximize their success, and how we treat PDAC with combined 5-FU and anti- CD25 therapies. Our data revealed that a synergistic combinatorial regimen targeting the Tregs and MDSCs in both crisp and fuzzy settings of model parameters can lead to tumor eradication.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08770-z","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T23:02:46Z","timestamp":1637017366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model"],"prefix":"10.1186","volume":"21","author":[{"given":"Sajad","family":"Shafiekhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojat","family":"Dehghanbanadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam Sadat","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Hadjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Homayoun","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"issue":"6","key":"8770_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"8770_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"8770_CR3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155.","journal-title":"Cancer Res"},{"issue":"1","key":"8770_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40364-018-0139-6","volume":"6","author":"MX Yang","year":"2018","unstructured":"Yang MX, Coates RF, Ambaye A, Gardner J-A, Zubarick R, Gao Y, et al. Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma. Biomark Res. 2018;6(1):25. https:\/\/doi.org\/10.1186\/s40364-018-0139-6.","journal-title":"Biomark Res"},{"issue":"1","key":"8770_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000347178","volume":"31","author":"T Hackert","year":"2013","unstructured":"Hackert T, B\u00fcchler MW. Pancreatic cancer: advances in treatment, results and limitations. Dig Dis. 2013;31(1):51\u20136. https:\/\/doi.org\/10.1159\/000347178.","journal-title":"Dig Dis"},{"issue":"6","key":"8770_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.2174\/138945012800564103","volume":"13","author":"V Corbo","year":"2012","unstructured":"Corbo V, Tortora G, Scarpa A. Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets. 2012;13(6):744\u201352. https:\/\/doi.org\/10.2174\/138945012800564103.","journal-title":"Curr Drug Targets"},{"issue":"10","key":"8770_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s12094-017-1681-7","volume":"19","author":"C Guillen-Ponce","year":"2017","unstructured":"Guillen-Ponce C, Blazquez J, Gonzalez I. de-Madaria E, Mont\u00e1ns J, Carrato a. diagnosis and staging of pancreatic ductal adenocarcinoma. Clin Transl Oncol. 2017;19(10):1205\u201316. https:\/\/doi.org\/10.1007\/s12094-017-1681-7.","journal-title":"Clin Transl Oncol"},{"key":"8770_CR8","first-page":"9354","volume":"20","author":"S Mohammed","year":"2014","unstructured":"Mohammed S, George Van Buren II, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol. 2014;20:9354.","journal-title":"World J Gastroenterol"},{"key":"8770_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jtbi.2016.06.021","volume":"406","author":"X Li","year":"2016","unstructured":"Li X, Xu J-X. A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy. J Theor Biol. 2016;406:42\u201351. https:\/\/doi.org\/10.1016\/j.jtbi.2016.06.021.","journal-title":"J Theor Biol"},{"issue":"5","key":"8770_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3760\/cma.j.issn.0529-5815.2017.05.018","volume":"55","author":"JQ Yang","year":"2017","unstructured":"Yang JQ, Wei T, Chen YW, Bai XL, Liang TB. Advances in immunotherapy of pancreatic ductal adenocarcinoma. Zhonghua Wai Ke Za Zhi. 2017;55(5):396\u2013400. https:\/\/doi.org\/10.3760\/cma.j.issn.0529-5815.2017.05.018.","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"2","key":"8770_CR11","first-page":"717","volume":"44","author":"TH Corbett","year":"1984","unstructured":"Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL\/6 mice. Cancer Res. 1984;44(2):717\u201326.","journal-title":"Cancer Res"},{"issue":"21","key":"8770_CR12","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2007.15.8469","volume":"26","author":"JM Herman","year":"2008","unstructured":"Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503\u201310. https:\/\/doi.org\/10.1200\/JCO.2007.15.8469.","journal-title":"J Clin Oncol"},{"issue":"7","key":"8770_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2217\/imt-2016-0142","volume":"9","author":"F Aroldi","year":"2017","unstructured":"Aroldi F, Zaniboni A. Immunotherapy for pancreatic cancer: present and future. Immunotherapy. 2017;9(7):607\u201316. https:\/\/doi.org\/10.2217\/imt-2016-0142.","journal-title":"Immunotherapy."},{"key":"8770_CR14","doi-asserted-by":"publisher","unstructured":"Tang Y, Xu X, Guo S, Zhang C, Tang Y, Tian Y, et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One. 2014;9(3). https:\/\/doi.org\/10.1371\/journal.pone.0091551.","DOI":"10.1371\/journal.pone.0091551"},{"issue":"4","key":"8770_CR15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/bjc.2013.32","volume":"108","author":"Y Ino","year":"2013","unstructured":"Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914\u201323. https:\/\/doi.org\/10.1038\/bjc.2013.32.","journal-title":"Br J Cancer"},{"issue":"18","key":"8770_CR16","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","volume":"12","author":"N Hiraoka","year":"2006","unstructured":"Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0369.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8770_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2051-1426-1-10","volume":"1","author":"R Wesolowski","year":"2013","unstructured":"Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells\u2013a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1(1):10. https:\/\/doi.org\/10.1186\/2051-1426-1-10.","journal-title":"J Immunother Cancer"},{"key":"8770_CR18","doi-asserted-by":"publisher","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills Tumor-associated Myeloid-derived suppressor cells resulting in enhanced t cell-dependent antitumor immunity. Cancer Res. 2010 [cited 2 Apr 2020]. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3690.","DOI":"10.1158\/0008-5472.CAN-09-3690"},{"key":"8770_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtbi.2018.01.006","volume":"442","author":"SP Shariatpanahi","year":"2018","unstructured":"Shariatpanahi SP, Shariatpanahi SP, Madjidzadeh K, Hassan M, Abedi-Valugerdi M. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: implications for therapeutic targeting strategies. J Theor Biol. 2018;442:1\u201310. https:\/\/doi.org\/10.1016\/j.jtbi.2018.01.006.","journal-title":"J Theor Biol"},{"issue":"12","key":"8770_CR20","doi-asserted-by":"publisher","first-page":"e0143840","DOI":"10.1371\/journal.pone.0143840","volume":"10","author":"C Loizides","year":"2015","unstructured":"Loizides C, Iacovides D, Hadjiandreou MM, Rizki G, Achilleos A, Strati K, et al. Model-based tumor growth dynamics and therapy response in a mouse model of de novo carcinogenesis. PLoS One. 2015;10(12):e0143840. https:\/\/doi.org\/10.1371\/journal.pone.0143840.","journal-title":"PLoS One"},{"issue":"1","key":"8770_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12976-015-0007-0","volume":"12","author":"E Castillo-Montiel","year":"2015","unstructured":"Castillo-Montiel E, Chimal-Eguia JC, Tello JI, Pi\u00f1on-Zar\u00e1te G, Herrera-Enr\u00edquez M, Castell-Rodr\u00edguez AE. Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model. Theor Biol Med Model. 2015;12(1):11. https:\/\/doi.org\/10.1186\/s12976-015-0007-0.","journal-title":"Theor Biol Med Model"},{"key":"8770_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jtbi.2014.02.028","volume":"351","author":"Y Louzoun","year":"2014","unstructured":"Louzoun Y, Xue C, Lesinski GB, Friedman A. A mathematical model for pancreatic cancer growth and treatments. J Theor Biol. 2014;351:74\u201382. https:\/\/doi.org\/10.1016\/j.jtbi.2014.02.028.","journal-title":"J Theor Biol"},{"issue":"1","key":"8770_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-018-1673-6","volume":"16","author":"N Pu","year":"2018","unstructured":"Pu N, Zhao G, Yin H, Li J, Nuerxiati A, Wang D, et al. CD25 and TGF-\u03b2 blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. J Transl Med. 2018;16(1):1\u201313. https:\/\/doi.org\/10.1186\/s12967-018-1673-6.","journal-title":"J Transl Med"},{"issue":"1-2","key":"8770_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.cell.2011.11.060","volume":"148","author":"H Haeno","year":"2012","unstructured":"Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1-2):362\u201375. https:\/\/doi.org\/10.1016\/j.cell.2011.11.060.","journal-title":"Cell."},{"issue":"9","key":"8770_CR25","doi-asserted-by":"publisher","first-page":"e1003231","DOI":"10.1371\/journal.pcbi.1003231","volume":"9","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Huang J, England CG, McNally LR, Frieboes HB. Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. PLoS Comput Biol. 2013;9(9):e1003231. https:\/\/doi.org\/10.1371\/journal.pcbi.1003231.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"8770_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","volume":"32","author":"T Condamine","year":"2011","unstructured":"Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19\u201325. https:\/\/doi.org\/10.1016\/j.it.2010.10.002.","journal-title":"Trends Immunol"},{"key":"8770_CR27","doi-asserted-by":"crossref","unstructured":"Abedi-Valugerdi M, Wolfsberger J, Pillai PR, Zheng W, Sadeghi B, Zhao Y, Hassan M. Suppressive effects of lowdose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. Int Immunopharmacol. 2016;40:41\u20139.","DOI":"10.1016\/j.intimp.2016.08.023"},{"key":"8770_CR28","doi-asserted-by":"crossref","unstructured":"de Pillis LG, Radunskaya A. A mathematical model of immune response to tumor invasion. In: Computational Fluid and Solid Mechanics 2003: Elsevier; 2003. p. 1661\u20138.","DOI":"10.1016\/B978-008044046-0.50404-8"},{"issue":"9","key":"8770_CR29","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.4049\/jimmunol.167.9.5247","volume":"167","author":"Y Kawarada","year":"2001","unstructured":"Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, H\u00e4mmerling GJ. NK-and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol. 2001;167(9):5247\u201353. https:\/\/doi.org\/10.4049\/jimmunol.167.9.5247.","journal-title":"J Immunol"},{"key":"8770_CR30","doi-asserted-by":"publisher","unstructured":"Kuznetsov VA. Basic models of tumor-immune system interactions identification, analysis and predictions. A survey of models for Tumor-Immune system dynamics. Springer; 1997:237\u2013294, DOI: https:\/\/doi.org\/10.1007\/978-0-8176-8119-7_6.","DOI":"10.1007\/978-0-8176-8119-7_6"},{"issue":"1","key":"8770_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1189\/jlb.0311177","volume":"91","author":"J Youn","year":"2012","unstructured":"Youn J, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91(1):167\u201381. https:\/\/doi.org\/10.1189\/jlb.0311177.","journal-title":"J Leukoc Biol"},{"key":"8770_CR32","unstructured":"Kyewski B, Suri-Payer E, eds. CD4+ CD25+ regulatory T cells: origin, function and therapeutic potential. Vol. 293. Springer Science & Business Media; 2005."},{"issue":"15","key":"8770_CR33","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1002\/mma.3887","volume":"39","author":"A Ghaffari","year":"2016","unstructured":"Ghaffari A, Bahmaie B, Nazari M. A mixed radiotherapy and chemotherapy model for treatment of cancer with metastasis. Math Methods Appl Sci. 2016;39(15):4603\u201317. https:\/\/doi.org\/10.1002\/mma.3887.","journal-title":"Math Methods Appl Sci"},{"issue":"01","key":"8770_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1142\/S021833901750005X","volume":"25","author":"D-H He","year":"2017","unstructured":"He D-H, Xu J-X. A mathematical model of pancreatic cancer with two kinds of treatments. J Biol Syst. 2017;25(01):83\u2013104. https:\/\/doi.org\/10.1142\/S021833901750005X.","journal-title":"J Biol Syst"},{"issue":"2","key":"8770_CR35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.bbrc.2016.03.128","volume":"473","author":"Y Wu","year":"2016","unstructured":"Wu Y, Gan Y, Yuan H, Wang Q, Fan Y, Li G, et al. Enriched environment housing enhances the sensitivity of mouse pancreatic cancer to chemotherapeutic agents. Biochem Biophys Res Commun. 2016;473(2):593\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2016.03.128.","journal-title":"Biochem Biophys Res Commun"},{"key":"8770_CR36","unstructured":"Rohatgi A. WebPlotDigitizer: Web based tool to extract data from plots, images, and maps. Austin; 2017. Available online at: https:\/\/arohatgi.info\/WebPlotDigitizer."},{"issue":"1","key":"8770_CR37","doi-asserted-by":"publisher","first-page":"21599","DOI":"10.1038\/srep21599","volume":"6","author":"H Peng","year":"2016","unstructured":"Peng H, Zhao W, Tan H, Ji Z, Li J, Li K, et al. Prediction of treatment efficacy for prostate cancer using a mathematical model. Sci Rep. 2016;6(1):21599. https:\/\/doi.org\/10.1038\/srep21599.","journal-title":"Sci Rep"},{"key":"8770_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"R Coletti","year":"2020","unstructured":"Coletti R, Leonardelli L, Parolo S, Marchetti L. A QSP model of prostate cancer immunotherapy to identify effective combination therapies. Sci Rep. 2020;10:1\u201318.","journal-title":"Sci Rep"},{"issue":"9","key":"8770_CR39","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s11538-013-9853-2","volume":"75","author":"W-C Lo","year":"2013","unstructured":"Lo W-C, Arsenescu RI, Friedman A. Mathematical model of the roles of T cells in inflammatory bowel disease. Bull Math Biol. 2013;75(9):1417\u201333. https:\/\/doi.org\/10.1007\/s11538-013-9853-2.","journal-title":"Bull Math Biol"},{"key":"8770_CR40","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.bspc.2020.102046","volume":"61","author":"Y Islam","year":"2020","unstructured":"Islam Y, Ahmad I, Zubair M, Shahzad K. Double integral sliding mode control of leukemia therapy. Biomed Signal Process Contr. 2020;61:102046. https:\/\/doi.org\/10.1016\/j.bspc.2020.102046.","journal-title":"Biomed Signal Process Contr"},{"key":"8770_CR41","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3389\/fonc.2020.596931","volume":"10","author":"M Zaid","year":"2020","unstructured":"Zaid M, Elganainy D, Dogra P, Dai A, Widmann L, Fernandes P, et al. Imaging-based subtypes of pancreatic ductal adenocarcinoma exhibit differential growth and metabolic patterns in the pre-diagnostic period: implications for early detection. Front Oncol. 2020;10:2629. https:\/\/doi.org\/10.3389\/fonc.2020.596931.","journal-title":"Front Oncol"},{"issue":"7","key":"8770_CR42","doi-asserted-by":"publisher","first-page":"e40677","DOI":"10.1371\/journal.pone.0040677","volume":"7","author":"MK Srivastava","year":"2012","unstructured":"Srivastava MK, Zhu L, Harris-White M, Kar U, Huang M, Johnson MF, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One. 2012;7(7):e40677. https:\/\/doi.org\/10.1371\/journal.pone.0040677.","journal-title":"PLoS One"},{"issue":"2","key":"8770_CR43","doi-asserted-by":"publisher","first-page":"e0149674","DOI":"10.1371\/journal.pone.0149674","volume":"11","author":"F Liu","year":"2016","unstructured":"Liu F, Heiner M, Yang M. Fuzzy stochastic petri nets for modeling biological systems with uncertain kinetic parameters. PLoS One. 2016;11(2):e0149674. https:\/\/doi.org\/10.1371\/journal.pone.0149674.","journal-title":"PLoS One"},{"key":"8770_CR44","doi-asserted-by":"publisher","unstructured":"Shafiekhani S, Rahbar S, Akbarian F, Jafari AH. Fuzzy Stochastic Petri Net with Uncertain Kinetic Parameters for Modeling Tumor-Immune System. In: 2018 25th Iranian conference on biomedical engineering and 2018 3rd international Iranian conference on biomedical engineering: ICBME 2018; 2019. https:\/\/doi.org\/10.1109\/ICBME.2018.8703573.","DOI":"10.1109\/ICBME.2018.8703573"},{"issue":"S4","key":"8770_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12918-018-0568-8","volume":"12","author":"F Liu","year":"2018","unstructured":"Liu F, Chen S, Heiner M, Song H. Modeling biological systems with uncertain kinetic data using fuzzy continuous petri nets. BMC Syst Biol. 2018;12(S4):63\u201374. https:\/\/doi.org\/10.1186\/s12918-018-0568-8.","journal-title":"BMC Syst Biol"},{"key":"8770_CR46","doi-asserted-by":"publisher","unstructured":"Marino S, Hogue IB, Ray CJ, Kirschner DE. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theoretical Biol. 2008:178\u201396. Academic Press. https:\/\/doi.org\/10.1016\/j.jtbi.2008.04.011.","DOI":"10.1016\/j.jtbi.2008.04.011"},{"key":"8770_CR47","doi-asserted-by":"crossref","unstructured":"Pianosi F, Sarrazin F, Wagener T. A Matlab toolbox for global sensitivity analysis. Environ Model Softw. 2015;70:80\u20135.","DOI":"10.1016\/j.envsoft.2015.04.009"},{"key":"8770_CR48","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.3389\/fimmu.2019.03070","volume":"10","author":"C Siret","year":"2020","unstructured":"Siret C, Collignon A, Silvy F, Robert S, Cheyrol T, Andr\u00e9 P, et al. Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma. Front Immunol. 2020;10:3070. https:\/\/doi.org\/10.3389\/fimmu.2019.03070.","journal-title":"Front Immunol"},{"issue":"7547","key":"8770_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate nonredundant immune mechanisms in cancer. Nature. 2015;520 (7547):373-7. https:\/\/doi.org\/10.1038\/nature14292.","journal-title":"Nature"},{"issue":"4","key":"8770_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/jid.2011.416","volume":"132","author":"T Fujimura","year":"2012","unstructured":"Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol. 2012;132(4):1239\u201346. https:\/\/doi.org\/10.1038\/jid.2011.416.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"8770_CR51","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.4049\/jimmunol.1201018","volume":"189","author":"E Schlecker","year":"2012","unstructured":"Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 2012;189(12):5602\u201311. https:\/\/doi.org\/10.4049\/jimmunol.1201018.","journal-title":"J Immunol"},{"issue":"13","key":"8770_CR52","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","volume":"68","author":"P Serafini","year":"2008","unstructured":"Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439\u201349. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6621.","journal-title":"Cancer Res"},{"issue":"5","key":"8770_CR53","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1189\/jlb.0911465","volume":"92","author":"SM Centuori","year":"2012","unstructured":"Centuori SM, Trad M, LaCasse CJ, Alizadeh D, Larmonier CB, Hanke NT, et al. Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-\u03b2-induced differentiation of CD4+ CD25+ FoxP3+ Tregs from CD4+ CD25\u2212 FoxP3\u2212 T cells. J Leukoc Biol. 2012;92(5):987\u201397. https:\/\/doi.org\/10.1189\/jlb.0911465.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"8770_CR54","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","volume":"13","author":"RB Holmgaard","year":"2015","unstructured":"Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 2015;13(2):412\u201324. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.077.","journal-title":"Cell Rep"},{"key":"8770_CR55","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cyto.2018.06.005","volume":"113","author":"GL Re","year":"2019","unstructured":"Re GL, Re FL, Doretto P, Del Conte A, Amadio M, Cozzi C, et al. Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. Cytokine. 2019;113:50\u201360.","journal-title":"Cytokine"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08770-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T23:02:55Z","timestamp":1637017375000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08770-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8770"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08770-z","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"assertion":[{"value":"13 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that no animals were involved in the present study. Since this study was the mathematical modeling using the experimental data of the other published articles, no ethical approval was necessary for mice models and experimental protocols. All methods were carried out in this study are in accordance with relevant guidelines provided by the Institutional Review Board of Tehran University of Medical Sciences. All experimental data used in this study are adapted from other published papers and we did not have any experimental studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have been read the submitted manuscript and agree with its submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1226"}}